• Esperion Announces Commercial Availability of NEXLIZET americanpharmaceuticalreview
    June 15, 2020
    Esperion announced NEXLIZETTM (bempedoic acid and ezetimibe) tablets, the first approved oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering combination medicine is now available in the U.S.
PharmaSources Customer Service